Distinct evolutionary paths to TKI resistance in NSCLC

Cell Cycle. 2018;17(3):298-299. doi: 10.1080/15384101.2016.1221024. Epub 2018 Jan 29.

Authors

Matthew J Niederst^{1

2}, Jeffrey A Engelman^{1

2}, Aaron N Hata^{1

2}

Affiliations

¹ a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.
² b Department of Medicine , Harvard Medical School , Boston , MA , USA.

No abstract available

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Neoplasm, Residual / pathology
Protein Kinase Inhibitors / therapeutic use*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors